Cell And Gene Therapy Forecasting: Critical Factors To Getting It Right

By Sean Walter, Sankalp Sethi, Prashant Khare, and Abhinay Manne

Innovation in cell and gene therapies (CGTs) is leading to rapid growth in the space and transforming standards of care—curing chronic diseases, transforming patient lives, and reducing burdens on healthcare systems around the world. However, the CGT value proposition of long-term efficacy from a one-time, complex treatment introduces a number of unique challenges.

Today’s commercial cell therapies are autologous, and most of today’s gene therapies are considered “in vivo.” Companies are working to develop allogeneic cell therapies, and there are gene therapies on the horizon (and a few already here) that are considered “ex vivo.” Learn about the challenges and fulfillment hurdles CGTs face today as well as the major considerations for developing CGT forecasts, critical to reflecting the core realities of these complex businesses.